Searched for
ZEPBOUND
US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss marketLilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity...- Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefitsEli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoa...
- US stocks today: S&P 500 and Nasdaq hit record closing highs as US and Iran agree to extend ceasefireThe S&P 500 and Nasdaq hit record closing highs as hopes of a US Iran ceasefire extension boosted sentiment. Investors also digested US inf...
- Gene therapy for cholesterol: Initial test results cheerA new gene editing medicine, VERVE-102, offers hope for millions with heart conditions. Eli Lilly's drug showed significant reductions in b...
- US Stocks: Eli Lilly raises annual forecasts as GLP-1 drugs fuel growthEli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...
- Diabetes type 2, weight loss treatment can be done under single procedure? Research reveals big health updateDiabetes type 2 treatment: Trial participants either underwent a procedure used to improve blood sugar control in type 2 diabetes called du...
- Eli Lilly Foundayo weight-loss pill vs Novo Nordisk Wegovy oral obesity treatment tablets: Which medicine is the most prescribed across U.S.?Eli Lilly Foundayo was approved in the U.S. on April 1, with prescriptions accepted immediately on LillyDirect, while shipping started on A...
- Social media is abuzz with weight-loss drug retatrutide and longevity goals. What is the drug all about?A new weight-loss drug, retatrutide, is generating excitement. This investigational medicine targets three hormone receptors, offering a po...
- LLY stock jumps 9%: Why Eli Lilly stock is soaring today - Mounjaro, Zepbound sales drive massive earnings beat and 2026 forecast stuns Wall StreetLLY stock today: Eli Lilly's stock saw a significant jump following impressive fourth-quarter results and a strong 2026 financial forecast....
- Eli Lilly cuts Zepbound price to widen access for obesity drugEli Lilly has reduced the cost of its popular obesity drug Zepbound for American patients. This move aims to make the treatment more access...
- Eli Lilly becomes first healthcare firm to hit $1 trillion market cap - here’s why LLY stock has jumped over 36% this yearEli Lilly stock today: Eli Lilly achieved a historic milestone, briefly touching a $1 trillion market cap. This success is driven by strong...
- Eli Lilly drops CVS drug plan for staff after Novo obesity deal: ReportEli Lilly is switching its employee drug benefit plan from CVS Health to Rightway, a move reportedly linked to CVS's decision to stop cover...
- Eli Lilly Q2 earnings beat expectations on Mounjaro, Zepbound sales, stock falls after obesity drug trial missLilly stock latest news: Eli Lilly's Q2 earnings soared, fueled by Mounjaro and Zepbound's impressive sales, leading to raised full-year gu...
- New data show most US patients now stay on Wegovy, Zepbound after a yearA recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in early 2024 continu...
- This anti-diabetic drug used for weight loss has been approved by US FDA: When will India see its launch?The FDA approves Zepbound, originally used for type 2 diabetes and weight loss, for treating obstructive sleep apnea (OSA) in obese adults....
- Zepbound: The new weight loss pill that’s set to beat Wegovy, according to Eli LillyEli Lilly’s Zepbound has outperformed Novo Nordisk’s Wegovy in a recent clinical trial, with patients losing more weight on average. While ...
- Americans hungry for weight-loss drugs grapple with supply and insurance hurdlesDespite supply chain issues easing, patients seeking weight-loss drugs like Wegovy and Zepbound are turning to cheaper compounded versions ...
- Lilly lifts sales forecast by $3 billion as weight-loss drug powers resultsAnalysts have said the companies will likely split the U.S. market roughly 50-50 by the end of 2024, as Lilly bolsters its manufacturing ca...
- Eli Lilly rises 6%; company raises 2024 sales forecast by $2 billionExplosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise its annual sales...
- Lilly rides wave of weight-loss drug demand, working to expand capacityShares were off about 1% at $696.82 after gaining about 11% in January, making Lilly the eighth largest company in the U.S. by market capit...
Load More
